| Name | Title | Contact Details |
|---|
WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.
Nars Cosmetics, Inc, division of Shiseido Cosmetics America Ltd. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New York, NY. To find more information about Nars Cosmetics, Inc, division of Shiseido Cosmetics America Ltd., please visit www.narscosmetics.com
Midmark Corporation makes medical, dental, and veterinary products and provides related services. It was founded in 1915 as The Cummings Machine Company.
P1 Dental Partners is a Dental Partnership Organization that puts patients first, maintains doctor autonomy, and aims for excellence in dentistry. Learn more.
Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes.